Table 5 Comparisons of USP2a expression and clinical outcomes of bladder cancer patients
From: Assess the expression of ubiquitin specific protease USP2a for bladder cancer diagnosis
Variables | Patients (%) | mRNA expression of USP2a (median with IQR; × 10^3 copies/μl) | p value |
|---|---|---|---|
NMIBC | |||
Recurrence | 0.756 | ||
No recurrence | 118 (64.1) | 200.2 (77.9–391.7) | |
Recurrence | 66 (35.9) | 157.6 (56.4–387.2) | |
Progression | 0.793 | ||
No progression | 162 (88.0) | 165.5 (65.0–355.3) | |
Progression | 22 (12.0) | 238.9 (58.7–122.3) | |
MIBC | |||
Progression | 0.912 | ||
No progression | 38 (31.4) | 112.6 (23.1–508.7) | |
Progression | 83 (68.6) | 115.2 (22.9–435.1) | |
Overall survival | 0.123 | ||
Alive | 49 (40.5) | 81.3 (16.1–483.3) | |
Death | 72 (59.5) | 128.3 (37.4–494.1) |